Vyne Therapeutics Inc (VYNE) - News Archive

Dosing Commences in Phase 1a Trial of BD2-Selective BET Inhibitor VYN202 by VYNE Therapeutics The advent of epigenetic modulation presents a burgeoning frontier in pharmaceutical sciences, offering promising avenues for...

VYNE Therapeutics Advances Potential Treatment for Vitiligo with Phase 2b TrialBridgewater, N.J., January 10, 2024 - VYNE Therapeutics Inc. (Nasdaq: VYNE), a leading clinical-stage biopharmaceutical company specializing...

Bridgewater, N.J. - Innovative clinical-stage biopharmaceutical company, VYNE Therapeutics Inc., has announced that its Chief Scientific Officer, Dr. Iain Stuart, will present groundbreaking findings from the Phase 1b t...

is pleased to document a milestone advance in the field of immuno-inflammatory conditions. On January 10, 2024, VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company poised at the forefront of medical innov...